title: Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
abstract: Tumor size is not a reliable marker for the assessment of early antivascular effects of antiangiogenics. In the present study, we used 200-microm in-plane high-resolution dynamic contrast-enhanced computed tomography (DCE-CT) to noninvasively assess the immediate antivascular effects of vandetanib in a subcutaneous human colon cancer (LoVo) xenograft model in nude rats and to investigate correlation between changes in CT perfusion parameters and tumor volume or immunohistochemical end points. At 3 to 4 weeks after LoVo cell implantation, the animal was gavaged with either vandetanib (50 mg/kg) or vehicle twice (22 hours apart) and scanned with a preclinical DCE-CT scanner before (0 hour) and after treatment (24 hours). Quantitative maps of blood flow (BF) and volume (BV) of the tumor were calculated from the acquired DCE-CT images. The rats were divided into nonhypovascular, hypovascular, and combined (regardless of vascularity) groups. In the nonhypovascular group, significant decreases in both tumor BF and BV were observed in the vandetanib-treated rats compared with increases in the vehicle-treated rats. A significant decrease in BV was detected in the vandetanib-treated rats in the combined group as well. No differences in tumor growth, vascular endothelial growth factor expression, microvessel density, or apoptosis were observed between vandetanib- and vehicle-treated rats in all three groups. These results demonstrate that BF and BV imaging biomarkers from DCE-CT imaging can be used for rapid monitoring of immediate (24 hours after) antimicrovascular effects of vandetanib on tumors, even in the absence of significant changes of tumor volume or clinically relevant immunohistochemical end points.
authors.affiliation: Lawson Health Research Institute, St Joseph's Health Care London, London, Ontario, Canada.
authors.forename: Joo Ho
authors.initials: JH
authors.lastname: Tai
authors.forename: Jean
authors.initials: J
authors.lastname: Tessier
authors.forename: Anderson J
authors.initials: AJ
authors.lastname: Ryan
authors.forename: Lisa
authors.initials: L
authors.lastname: Hoffman
authors.forename: Xiaogang
authors.initials: X
authors.lastname: Chen
authors.forename: Ting-Yim
authors.initials: TY
authors.lastname: Lee
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D003287:Contrast Media; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007700:Kinetics; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D011923:Rats, Nude; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods*; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D003287:Contrast Media; D010880:Piperidines; D011799:Quinazolines; C452423:vandetanib
references.citation: J Comput Assist Tomogr. 2003 Sep-Oct;27(5):687-93
references.pmid: 14501359
references.citation: Am J Pathol. 1995 Jul;147(1):9-19
references.pmid: 7541613
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2831-42
references.pmid: 12807936
references.citation: NMR Biomed. 2008 Jan;21(1):42-52
references.pmid: 17458919
references.citation: Am J Pathol. 2003 Jan;162(1):183-93
references.pmid: 12507901
references.citation: Nucl Med Biol. 2007 Jul;34(5):483-92
references.pmid: 17591548
references.citation: N Engl J Med. 2008 May 8;358(19):2039-49
references.pmid: 18463380
references.citation: Radiology. 2005 Mar;234(3):785-92
references.pmid: 15734934
references.citation: Nat Med. 2003 Jun;9(6):685-93
references.pmid: 12778167
references.citation: Br J Cancer. 2005 Jun;92 Suppl 1:S6-13
references.pmid: 15928657
references.citation: Mol Cancer Ther. 2004 Sep;3(9):1041-8
references.pmid: 15367698
references.citation: Mol Cancer Ther. 2007 Feb;6(2):471-83
references.pmid: 17308046
references.citation: Am J Pathol. 2004 Jul;165(1):35-52
references.pmid: 15215160
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: AJR Am J Roentgenol. 2009 Aug;193(2):304-13
references.pmid: 19620425
references.citation: N Engl J Med. 1991 Jan 3;324(1):1-8
references.pmid: 1701519
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: Radiology. 2007 Aug;244(2):486-93
references.pmid: 17641369
references.citation: AJR Am J Roentgenol. 2008 Jul;191(1):133-9
references.pmid: 18562736
references.citation: Q J Nucl Med. 2003 Sep;47(3):171-87
references.pmid: 12897709
references.citation: J Clin Oncol. 2005 Feb 10;23(5):1011-27
references.pmid: 15585754
references.citation: J Clin Oncol. 2007 Jul 20;25(21):3045-54
references.pmid: 17634482
references.citation: Neuroimage. 2008 Mar 1;40(1):26-34
references.pmid: 18187345
references.citation: Mol Cancer Ther. 2007 Aug;6(8):2198-208
references.pmid: 17699717
references.citation: J Natl Cancer Inst. 2002 Jun 19;94(12):883-93
references.pmid: 12072542
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: Cancer Res. 2002 Aug 15;62(16):4645-55
references.pmid: 12183421
references.citation: Cancer Cell. 2005 Oct;8(4):269-71
references.pmid: 16226701
references.citation: Acad Radiol. 2000 Oct;7(10):840-50
references.pmid: 11048881
references.citation: Mol Imaging. 2004 Jul;3(3):149-58
references.pmid: 15530250
references.citation: Cancer. 2009 May 15;115(10 Suppl):2282-9
references.pmid: 19402071
references.citation: Radiology. 2008 Nov;249(2):510-7
references.pmid: 18812560
references.citation: Nat Clin Pract Oncol. 2006 Jan;3(1):24-40
references.pmid: 16407877
references.citation: Oncologist. 2008 Feb;13(2):120-5
references.pmid: 18305056
references.citation: Med Phys. 2007 Nov;34(11):4526-44
references.pmid: 18072519
references.citation: Nature. 2005 Dec 15;438(7070):932-6
references.pmid: 16355210
references.citation: N Engl J Med. 1995 Dec 28;333(26):1757-63
references.pmid: 7491141
references.citation: Science. 2006 May 26;312(5777):1171-5
references.pmid: 16728631
references.citation: Cancer Chemother Pharmacol. 2009 Sep;64(4):665-72
references.pmid: 19184020
references.citation: Invest Radiol. 2009 May;44(5):265-70
references.pmid: 19346961
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: Br J Radiol. 2003 Apr;76(904):220-31
references.pmid: 12711641
references.citation: Nat Med. 2004 Feb;10(2):145-7
references.pmid: 14745444
references.citation: Ann Oncol. 2009 Mar;20(3):486-91
references.pmid: 19088171
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Cancer Res. 1989 Jul 1;49(13):3506-12
references.pmid: 2731172
references.citation: Anticancer Drugs. 2007 Jun;18(5):569-79
references.pmid: 17414626
references.citation: Radiology. 2005 Oct;237(1):151-8
references.pmid: 16183931
references.citation: Brain. 1998 Jul;121 ( Pt 7):1369-79
references.pmid: 9679787
references.citation: Lung Cancer. 2001 Nov;34(2):233-41
references.pmid: 11679182
references.citation: Acad Radiol. 2000 Oct;7(10):800-11
references.pmid: 11048878
references.citation: J Comput Assist Tomogr. 2009 Jul-Aug;33(4):552-9
references.pmid: 19638848
references.citation: J Angiogenes Res. 2009 Sep 21;1:5
references.pmid: 19946413
references.citation: J Nucl Med. 1984 Sep;25(9):972-7
references.pmid: 6088735